MA44631A - Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 - Google Patents

Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6

Info

Publication number
MA44631A
MA44631A MA044631A MA44631A MA44631A MA 44631 A MA44631 A MA 44631A MA 044631 A MA044631 A MA 044631A MA 44631 A MA44631 A MA 44631A MA 44631 A MA44631 A MA 44631A
Authority
MA
Morocco
Prior art keywords
depression
receiver
agents
link
treatment
Prior art date
Application number
MA044631A
Other languages
English (en)
French (fr)
Inventor
Guang Chen
Yu Sun
Dai Wang
Gayle Wittenberg
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA44631A publication Critical patent/MA44631A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044631A 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6 MA44631A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319558P 2016-04-07 2016-04-07

Publications (1)

Publication Number Publication Date
MA44631A true MA44631A (fr) 2019-02-13

Family

ID=59998986

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044631A MA44631A (fr) 2016-04-07 2017-04-06 Traitement de la dépression à l'aide d'agents qui bloquent la liaison de l'il-6 au récepteur de l'il-6

Country Status (7)

Country Link
US (1) US20170291942A1 (enExample)
EP (1) EP3440108A4 (enExample)
JP (1) JP2019519470A (enExample)
AU (1) AU2017248280A1 (enExample)
CA (1) CA3019828A1 (enExample)
MA (1) MA44631A (enExample)
WO (1) WO2017177032A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019215701A1 (en) * 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004671A (es) * 2001-11-14 2005-08-25 Johnson & Johnson Anticuerpos anti-interleucina-6, composiciones, metodos y usos.
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
BRPI1007005A2 (pt) * 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
JP6347477B2 (ja) * 2013-12-27 2018-06-27 国立大学法人千葉大学 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法

Also Published As

Publication number Publication date
US20170291942A1 (en) 2017-10-12
WO2017177032A3 (en) 2017-11-16
WO2017177032A2 (en) 2017-10-12
CA3019828A1 (en) 2017-10-12
JP2019519470A (ja) 2019-07-11
AU2017248280A1 (en) 2018-10-25
EP3440108A2 (en) 2019-02-13
EP3440108A4 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3661955A4 (en) CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MA45036A (fr) Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
EP3334484A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING HYPOXIA OR HYPOXIA RESPONSE FOR THE TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STEM DISEASES
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3504187A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY
EP3474863A4 (en) Phosphoramidates for the treatment of hepatitis b virus
SI3464266T1 (sl) Substituirani indazoli, uporabni pri zdravljenju in preprečevanju alergijskih in/ali vnetnih bolezni pri živalih
EP3506943A4 (en) METHOD AND COMPOSITIONS WITH INTERLEUKIN 6 RECEPTOR ALPHA BINDING SINGLE CHAIN VARIABLE FRAGMENTS
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
EP3820888A4 (en) CO-RECEPTOR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASES
EP3355889A4 (en) DIAMINOPYRIMIDINE P2X3 AND P2X2 / 3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF HUSTEN
EP3512517A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF ANXIETY AND DEPRESSION
EP3403675A4 (en) ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA
EP3677266A4 (en) EXON-18 AND / OR EXON-21 MUTANTS EGFR SELECTIVE INHIBITOR
EP3522912A4 (en) HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
EP3723787A4 (en) DARIC INTERLEUKIN RECEPTORS
EP3716966A4 (en) ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA
EP3612214A4 (en) ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
MA53875A (fr) Traitement avec des compositions d'igg hautement sialylées
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3632431A4 (en) Agent for preventing or treating brain atrophy
EP3442538A4 (en) TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE